Liraglutide vs Tirzepatide
Liraglutide is an earlier, once-daily GLP-1 analogue; tirzepatide is a newer once-weekly dual agonist. They mark two generations of incretin research.
Liraglutide
A once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analogue developed by acylation, predecessor to semaglutide.
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
Tirzepatide
Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors.
BEST STUDIED FOR
Dual-agonist (GIP/GLP-1) metabolic research
FREE GIFTFree GHK-Cu 50 mg with every Tirzepatide 30mg vial and free GHK-Cu 100 mg with every Tirzepatide 60mg vial, until 15 Oct — one per vial, added automatically at checkout.
Side by side · to buy
Price, purity and dispatch
| Compare | Liraglutide | Tirzepatide30 mg · more sizes |
|---|---|---|
| Price | — | fromR1,399 |
| Cost per mg | — | R46.6 / mg |
| Purity (Janoshik) | — | 99.927%HPLC, published |
| Stock | — | Restocking |
| Dispatch | — | When restocked |
| Certificate | — | View CoA → |
| Literature | — | 3 papers → |
| Research focus | Incretin & metabolic | Dual-agonist (GIP/GLP-1) metabolic research |
| Read the cited profile | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Liraglutide | Tirzepatide | |
|---|---|---|
| The key difference | Daily GLP-1 agonist | Weekly GIP/GLP-1 dual agonist |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Liraglutide carries a C16 fatty-acid side chain that allows albumin binding and self-association, extending its half-life to about 13 hours. | Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors. |
| Status | Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa. | An approved medicine (US/EU) for type 2 diabetes and obesity. |
| Reported safety signals | Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented. | Phase 3 trials reported mainly gastrointestinal adverse events (nausea, diarrhoea, vomiting). |
| A key study | Traces how acylation strategies extended GLP-1’s half-life, first in liraglutide and then semaglutide. (Front Endocrinol (Lausanne) 2019, PMID 31031702) | The discovery-to-proof-of-concept study characterising LY3298176 (tirzepatide) as a novel dual GIP/GLP-1 receptor agonist. (Mol Metab 2018, PMID 30473097) |
WHEN TO RESEARCH WHICH
Liraglutide gives the long-term safety record; tirzepatide the newer dual-agonist efficacy data. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Liraglutide] The Discovery and Development of Liraglutide and Semaglutide — Front Endocrinol (Lausanne) 2019. PMID 31031702
- [Liraglutide] A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med 2015. PMID 26132939
- [Liraglutide] Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies — J Clin Med 2025. PMID 40507553
- [Tirzepatide] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept — Mol Metab 2018. PMID 30473097
- [Tirzepatide] Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — N Engl J Med 2021. PMID 34170647
- [Tirzepatide] Tirzepatide Once Weekly for the Treatment of Obesity — N Engl J Med 2022. PMID 35658024
FREQUENTLY ASKED
What is the difference between Liraglutide and Tirzepatide?
Liraglutide is an earlier, once-daily GLP-1 analogue; tirzepatide is a newer once-weekly dual agonist. They mark two generations of incretin research.
What is the regulatory status of Liraglutide and Tirzepatide?
Liraglutide: Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa. Tirzepatide: An approved medicine (US/EU) for type 2 diabetes and obesity.
What safety signals have been reported?
Liraglutide: Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented. Tirzepatide: Phase 3 trials reported mainly gastrointestinal adverse events (nausea, diarrhoea, vomiting).
Which studies is this comparison based on?
For Liraglutide: “The Discovery and Development of Liraglutide and Semaglutide” (PMID 31031702); “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management” (PMID 26132939); “Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies” (PMID 40507553). For Tirzepatide: “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept” (PMID 30473097); “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes” (PMID 34170647); “Tirzepatide Once Weekly for the Treatment of Obesity” (PMID 35658024).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use